Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Traverse City, MI
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Traverse City, MI
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Dayton, OH
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Round Rock, TN
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Round Rock, TN
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Burlington, VT
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Ft. Wayne, IN
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Ft. Wayne, IN
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Shreveport, LA
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
St Louis, MO
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
New York, NY
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Charlotte, NC
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Seattle, WA
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Investigational Site Number 1405
mi
from
Geelong,
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Investigational Site Number 1405
mi
from
Geelong,
Click here to add this to my saved trials
Protection Against Potential Brain Injury During Competitive Football
Novel Protection Against Potential Brain Injury During Competitive Football Head Impacts
Status: Enrolling
Updated:  2/25/2016
Cincinanti Childrens Hospital Medical Center
mi
from
Cincinnati, OH
Protection Against Potential Brain Injury During Competitive Football
Novel Protection Against Potential Brain Injury During Competitive Football Head Impacts
Status: Enrolling
Updated: 2/25/2016
Cincinanti Childrens Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Effects of Breathing and Walking Treatments on Recovery Post-Spinal Cord Injury
Intermittent Hypoxia and Locomotor Training: Effects Following SCI
Status: Enrolling
Updated:  2/26/2016
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
Effects of Breathing and Walking Treatments on Recovery Post-Spinal Cord Injury
Intermittent Hypoxia and Locomotor Training: Effects Following SCI
Status: Enrolling
Updated: 2/26/2016
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
Status: Enrolling
Updated:  2/26/2016
Massachusetts General Hospital
mi
from
Boston, MA
A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
Status: Enrolling
Updated: 2/26/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Washington,
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Baltimore, MD
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Boston, MA
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
New Brunswick, NJ
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
mi
from
Lille,
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
mi
from
Lille,
Click here to add this to my saved trials
Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
Status: Enrolling
Updated:  2/26/2016
Partners MS Center, 1 Brookline Place Suite 225
mi
from
Brookline, MA
Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
Status: Enrolling
Updated: 2/26/2016
Partners MS Center, 1 Brookline Place Suite 225
mi
from
Brookline, MA
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
University of Alabama At Birmingham, Pediatric Neurology Childrens, Harbor Bldg Suite 314, 1600 7Th Avenue South
mi
from
Birmingham, AL
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
University of Alabama At Birmingham, Pediatric Neurology Childrens, Harbor Bldg Suite 314, 1600 7Th Avenue South
mi
from
Birmingham, AL
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Mayo Clinic Arizona, 13400 East Shea Boulevard, Csu-Cp21B
mi
from
Scottsdale, AZ
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Mayo Clinic Arizona, 13400 East Shea Boulevard, Csu-Cp21B
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
WASHINGTON REGIONAL MEDICAL CENTER, 3215 N. North Hills Blvd
mi
from
Fayetteville, AR
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
WASHINGTON REGIONAL MEDICAL CENTER, 3215 N. North Hills Blvd
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
University of California Irvine, Department of Neurology, 100 Irvine Hall
mi
from
Irvine, CA
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
University of California Irvine, Department of Neurology, 100 Irvine Hall
mi
from
Irvine, CA
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
University of California Davis, Medical Center Dept of Neurology, Acc Building Suite 3700, 4860 Y Street
mi
from
Sacramento, CA
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
University of California Davis, Medical Center Dept of Neurology, Acc Building Suite 3700, 4860 Y Street
mi
from
Sacramento, CA
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Colorado Neurological Institute, Movement Disorders Center, 701 East Hampden Avenue Suite 510
mi
from
Littleton, CO
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Colorado Neurological Institute, Movement Disorders Center, 701 East Hampden Avenue Suite 510
mi
from
Littleton, CO
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
University of Florida Center for Movement Disorders and Neurorestoration, 3450 Hull Road, 4th Floor
mi
from
Gainesville, FL
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
University of Florida Center for Movement Disorders and Neurorestoration, 3450 Hull Road, 4th Floor
mi
from
Gainesville, FL
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
University of South Florida, College of Medicine Dept of Neurology, 12901 Bruce B Downs Blvd Mdc-55
mi
from
Tampa, FL
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
University of South Florida, College of Medicine Dept of Neurology, 12901 Bruce B Downs Blvd Mdc-55
mi
from
Tampa, FL
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Emory University, Wesley Woods Center, 1841 Clifton Road NE Room 314
mi
from
Atlanta, GA
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Emory University, Wesley Woods Center, 1841 Clifton Road NE Room 314
mi
from
Atlanta, GA
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Idaho Elks Rehabilitation Hospital, 600 North Robbins Road
mi
from
Boise, ID
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Idaho Elks Rehabilitation Hospital, 600 North Robbins Road
mi
from
Boise, ID
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Rush University Medical Center, Department of Neurological Sciences, 1725 West Harrison Suite 755
mi
from
Chicago, IL
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Rush University Medical Center, Department of Neurological Sciences, 1725 West Harrison Suite 755
mi
from
Chicago, IL
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Indiana University School of Medicine, Outpatient Clinical Research Facility, 535 Barnhill Drive Room #150
mi
from
Indianapolis, IN
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Indiana University School of Medicine, Outpatient Clinical Research Facility, 535 Barnhill Drive Room #150
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
University of Iowa Hospital and Clinics, 200 Hawkins Road, Room W263 General Hospital
mi
from
Iowa City, IA
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
University of Iowa Hospital and Clinics, 200 Hawkins Road, Room W263 General Hospital
mi
from
Iowa City, IA
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
University of Kansas Medical Center, Department of Neurology, 3599 Rainbow Blvd Mail Stop 2012
mi
from
Kansas City, KA
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
University of Kansas Medical Center, Department of Neurology, 3599 Rainbow Blvd Mail Stop 2012
mi
from
Kansas City, KA
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Johns Hopkins University, 600 North Wolfe Street, Meyer 2-181
mi
from
Baltimore, MD
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Johns Hopkins University, 600 North Wolfe Street, Meyer 2-181
mi
from
Baltimore, MD
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
University of Maryland School of Medicine, 22 South Greene Street, N4 W49-B
mi
from
Baltimore, MD
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
University of Maryland School of Medicine, 22 South Greene Street, N4 W49-B
mi
from
Baltimore, MD
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Boston University School of Medicine, Department of Neurology, 715 Albany Street C329
mi
from
Boston, MA
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Boston University School of Medicine, Department of Neurology, 715 Albany Street C329
mi
from
Boston, MA
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Massachusetts General Hospital, 149 13Th Street Suite 2241
mi
from
Charlestown, MA
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Massachusetts General Hospital, 149 13Th Street Suite 2241
mi
from
Charlestown, MA
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
University of Michigan, 1500 E Medical Center Drive, B1 H202 Nuclear Medicine
mi
from
Ann Arbor, MI
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
University of Michigan, 1500 E Medical Center Drive, B1 H202 Nuclear Medicine
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Struthers Parkinson'S Center, 6701 Country Club Drive
mi
from
Golden Valley, MN
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Struthers Parkinson'S Center, 6701 Country Club Drive
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Washington University School of Medicine, Box 8111, 660 South Euclid
mi
from
St Louis, MO
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Washington University School of Medicine, Box 8111, 660 South Euclid
mi
from
St Louis, MO
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
University of Las Vegas School of Medicine, 1707 W. Charleston Blvd, Suite 220
mi
from
Las Vegas, NV
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
University of Las Vegas School of Medicine, 1707 W. Charleston Blvd, Suite 220
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Nj Neuroscience Institute, Jfk Medical Center, 65 James Street
mi
from
Edison, NJ
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Nj Neuroscience Institute, Jfk Medical Center, 65 James Street
mi
from
Edison, NJ
Click here to add this to my saved trials
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated:  2/29/2016
Albany Medical College, Parkinson'S Disease & Movement Disorders Ctr
mi
from
Albany, NY
Coenzyme Q10 in Huntington's Disease (HD)
Coenzyme Q10 in Huntington's Disease (HD)
Status: Enrolling
Updated: 2/29/2016
Albany Medical College, Parkinson'S Disease & Movement Disorders Ctr
mi
from
Albany, NY
Click here to add this to my saved trials